Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

COPD (Chronic Obstructive Pulmonary Disease) Clinical Trials

A listing of COPD (Chronic Obstructive Pulmonary Disease) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (14) clinical trials

We will examine whether or not lebrikizumab improves lung function in people with COPD. We also hope to learn whether lebrikizumab reduces the number of COPD exacerbations and improves symptoms in people who do not have good control of their COPD despite being treated with a long-acting bronchodilator and an ...


The purpose of the study is to evaluate the effectiveness, tolerability, safety as well as lung function study of 4 different doses of (an experimental long-lasting anticholinergic) substance, glycopyrronium bromide pMDI (pressurized metered dose inhalation), compared to a placebo and a marketed version of another long-lasting anticholinergic, Triopropium Bromide (Spiriva ...


A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease

Enrolled participants will be randomly assigned to 1 of 2 treatment sequences and will receive both CK-2127107 and matching placebo over 2 treatment periods.


A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients

Roflumilast is a product which has been approved for the treatment of severe chronic obstructive lung disease (COPD) and its approved dose is 500μg once daily. This study is primarily designed to see whether alternation in this dose can improve tolerability of Roflumilast in COPD patients. Therefore one in three ...


A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota

This is a randomized, non-placebo controlled study to evaluate the effects of Symbicort 400 mcg twice daily (BID) and Advair 250 mcg BID over 12 weeks. As the standard of therapy for COPD is a long-acting muscarinic antagonist (LAMA) treatment, a placebo only group cannot be ethically justified. The control ...